Clinical Trial Update: KAT-101 in Subjects With Hepatocellular Carcinoma (HCC) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of KAT-101 for hepatocellular carcinoma and fibrolamellar carcinoma has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrolamellar Carcinoma
• Hepatocellular Carcinoma

Drugs mentioned

• KAT-101

Snippet

Sponsor: Primocure Pharma | Conditions: Hepatocellular Carcinoma, Fibrolamellar Carcinoma | Phase 1, Phase 2 | Status: SUSPENDED